Anadys Pharma (ANDS) Completes ANA598 Dosing in Phase II in HCV Patients
Tweet Send to a Friend
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that ANA598 dosing has been completed in the first dose cohort, 200 mg ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
